Skip to main content
Click Here For COVID-19 Studies
Home
Clinical Trials Office Register as a Researcher Log In
366 Studies Now Enrolling
 Menu
Home How It Works Resources Join RecruitMe

Search

Reset

Status

  • Show all (51)
  • (-) Currently Recruiting (2)
  • Closed (49)

Medical Condition

  • Show all (366)
  • Addiction (2)
  • Allergy, Asthma, & Immunology (1)
  • Autoimmune Disorders (2)
  • (-) Blood Disorders (1)
    • Amyloidosis (1)
  • Bone & Muscle (2)
  • Cancer (109)
    • (-) Bladder Cancer (1)
    • Brain Cancer (9)
    • Breast Cancer (7)
    • Gastrointestinal (3)
    • Gynecologic Cancer (9)
    • Kidney Cancer (1)
    • Leukemia (8)
    • Liver Cancer (2)
    • Lung Cancer (6)
    • Lymphoma (12)
    • Multiple Myeloma (8)
    • Pancreatic Cancer (7)
    • Prostate Cancer (6)
    • Skin Cancer (2)
  • Child Development (1)
  • COVID-19 (Coronavirus) (10)
  • Diabetes (9)
  • Ear, Nose and Throat (6)
  • Endocrine & Metabolic Disease (2)
  • Gastrointestinal and Digestive Diseases (3)
  • Hair and Skin Disorders (1)
  • Healthy Volunteers (45)
  • Heart Disease (25)
  • Infectious Disease (12)
  • Liver Disease (14)
  • Lung Disease (3)
  • Neurological Disorders (45)
  • Nutrition (1)
  • Obesity (8)
  • Obstetrics & Gynecology (12)
  • Pediatrics (26)
  • Psychiatric Disorders (8)
  • Rehabilitation (1)
  • Stroke (2)
  • Transplant (15)
Displaying 1 - 2 of 2

Evaluating the Efficacy & Safety of Autogene Cevumeran + Nivolumab VS Nivolumab Alone for High-Risk Muscle-Invasive Urothelial Carcinoma

Condition: Cancer / Bladder Cancer
Investigator: Alexander Wei, MD
Status: Currently Recruiting
This study is testing a drug called autogene cevumeran in combination with nivolumab, a cancertreatment drug known for treating bladder cancer. The purpose of this study is to compare the effects, good or bad, of autogene cevumeran plus nivolumab versus nivolumab on patients with Muscle Invasive Urothelial Carcinoma (MIUC.) In this study, you will get…
Read More

Study of ABBV-383 in Patients with Amyloidosis

Condition: Blood Disorders / Amyloidosis
Investigator: Rajshekhar Chakraborty, MD
Status: Currently Recruiting
The purpose of this study is to see how safe and effective is the study drug, ABBV-383. ABBV-383 works by binding to a specific protein called B-cell maturation antigen, which is found on the surface of cells affected by amyloidosis. By engaging T-cells, a type of white blood cell, ABBV-383 helps activate the immune response to target and remove the…
Read More
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE
COMPLIANCE
Compliance Hotline Compliance Program
RESOURCES
Contact RecruitMe Terms of Use Privacy Policy ©2025 Columbia University
SCHOOLS
Vagelos College of Physicians and Surgeons Mailman School of Public Health School of Nursing College of Dental Medicine Graduate School of Arts and Science